Camphidin | 78339-85-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: Camphidin
• 英文别名: 1,8,8-trimethyl-3-azabicyclo[3.2.1]-oct-3-ane；1,8,8-Trimethyl-3-azabicyclo[3.2.1]octane
• CAS: 78339-85-2
• 化学式: C₁₀H₁₉N
• mdl: MFCD01111067
• 分子量: 153.268
• InChiKey: CHRAJVQLWOMYQI-UHFFFAOYSA-N

物化性质

• 沸点：
  186.1±8.0 °C(Predicted)
• 密度：
  0.890±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Camphidin 、 利福霉素 生成 3-((1Ξ)-1,8,8-trimethyl-3-aza-bicyclo[3.2.1]oct-3-yl)-rifamycin
  参考文献：
  名称：

  Zur Kenntnis von Rifamycin-S. Reaktionen des chinoiden Nucleus. Modifikationen von Antibiotica, 9. Mitteilung [1]

  摘要：

  AbstractThe reactivity of rifamycin‐S (1) with respect to nucleophilic reagents has been studied. Several new classes of derivatives, some of which show interesting biological activities, are described.

  DOI：

  10.1002/hlca.19730560720
• 作为产物：
  描述：

  (1R,5S)-1,8,8-trimethyl-3-oxabicyclo[3.2.1]octan-2-one 在 乙醇 、 氨 、 zinc(II) chloride 作用下， 生成 Camphidin
  参考文献：
  名称：

  Rupe; Jaeggi, Helvetica Chimica Acta, 1920, vol. 3, p. 655

  摘要：

  DOI：

文献信息

• [EN] PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS D'ACIDE PYRIDIN-3-YL ACÉTIQUE COMME INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE UK (NO 5) LTD

  公开号：WO2017025864A1

  公开（公告）日：2017-02-16

  Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. In the compounds of formula (I), R1 is selected from H, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (alkoxy)alkoxyalkyl, or (R6)alkyl; R2 is phenyl substituted with 1 R7 substituent and with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; or R2 is selected from tetrahydroisoquinolinyl, ((Ar1)alkyl)tetrahydroisoquinolinyl, or ((N-alkoxycarbonyl)tetrahydroisoquinolinyl; R3 is is selected from tetrahydroisoquinolinyl or decahydroisoquinolinyl and is substituted with 0-3 substituents selected from halo, alkyl, and haloalkyl; or R3 is a [5-7.3-7.0-2] fused or bridged bicyclic amine and is substituted with 0-3 alkyl substituents; or R3 is selected from azetidinyl, pyrrolidinyl, piperidinyl, or homopiperidinyl and contains a spirocyclic moiety wherein the spirocyclic moiety, including the carbon atom to which it is attached, forms C3-7 cycloalkane, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, N-alkylpyrrolidinyl, piperidinyl, N-alkylpiperidinyl, homopiperidinyl, or N-alkylpiperidinyl, and wherein the spirocyclic moiety is substituted with 0-3 halo or alkyl substituents; R4 is selected from alkyl or haloalkyl; R5 is selected from H, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (alkoxy)alkoxyalkyl, or (R6)alkyl; R6is selected from (oxetanyl)oxy, ((oxetanyl)alkoxy)alkyl, (tetrahydropyranyloxy)alkyl, (tetrahydropyranyl)alkoxy)alkyl, or (Rg)(R9)N; R7 is selected from (Ar1)alkoxy or ((Ar1)alkyl)HNCO; R8 is selected from hydrogen, alkyl, (cycloalkyl)alkyl, alkoxyalkyl, (tetrahydropyanyl)alkyl, tetrahydropyanyl, or alkoxyphenyl; R9 is selected from hydrogen or alkyl; or (R8)(R9)N taken together is selected from azetidinyl, pyrrolidinyl, piperidinyl, (spirocyclobutyl)piperidinyl, piperazinyl, or morpholinyl; and Ar1 is phenyl substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy.

  化合物的结构式（I）包括药学上可接受的盐，包含这些化合物的药物组合物，制备这些化合物的方法以及它们在抑制HIV整合酶和治疗HIV或艾滋病感染者中的用途。在结构式（I）的化合物中，R1从H，烷基，卤代烷基，羟基烷基，烷氧基烷基，（烷氧基）烷氧基烷基或（R6）烷基中选择；R2是苯基，其上取代有1个R7取代基，以及从卤素，烷基，卤代烷基，烷氧基和卤代烷氧基中选择0-3个取代基；或者R2从四氢异喹啉基，（（Ar1）烷基）四氢异喹啉基，或（（N-烷氧羰基）四氢异喹啉基中选择；R3从四氢异喹啉基或十氢异喹啉基中选择，并取代有从卤素，烷基和卤代烷基中选择的0-3个取代基；或者R3是[5-7.3-7.0-2]融合或桥接的双环胺基，并取代有0-3个烷基取代基；或者R3从氮杂环丙烷基，吡咯啉基，哌啶基，或异哌啶基中选择，并含有一个螺环结构基团，其中螺环结构基团，包括与其相连的碳原子，形成C3-7环烷烃，四氢呋喃基，四氢吡喃基，吡咯啉基，N-烷基吡咯啉基，哌啶基，N-烷基哌啶基，异哌啶基，或N-烷基哌啶基，并且螺环结构基团取代有0-3个卤素或烷基取代基；R4从烷基或卤代烷基中选择；R5从H，烷基，卤代烷基，羟基烷基，烷氧基烷基，（烷氧基）烷氧基烷基或（R6）烷基中选择；R6从（氧杂环丙烷基）氧，（（氧杂环丙烷基）烷氧基）烷基，（四氢吡喃氧基）烷基，（四氢吡喃基）烷氧基）烷基，或（Rg）（R9）N中选择；R7从（Ar1）烷氧基或（（Ar1）烷基）HNCO中选择；R8从氢，烷基，（环烷基）烷基，烷氧基烷基，（四氢吡啶基）烷基，四氢吡啶基，或烷氧基苯基中选择；R9从氢或烷基中选择；或者（R8）（R9）N共同选择自氮杂环丙烷基，吡咯啉基，哌啶基，（螺环丁基）哌啶基，哌嗪基，或吗啉基；Ar1是苯基，其上取代有从卤素，烷基，卤代烷基，烷氧基和卤代烷氧基中选择的0-3个取代基。
• PHARMACEUTICAL USE OF SUBSTITUTED AMIDES
  申请人：Andersen Henrik Sune

  公开号：US20090124598A1

  公开（公告）日：2009-05-14

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  描述了使用替代酰胺来调节11β-羟基类固醇脱氢酶1（11βHSD1）活性以及将这些化合物用作药物组合物的用途。还描述了一类新型的替代酰胺，它们在治疗中的应用，包含这些化合物的药物组合物，以及它们在制造药物中的应用。目前的化合物是11βHSD1活性的调节剂，更具体地是抑制剂，并且可能在治疗一系列医学疾病中有用，其中降低细胞内活性糖皮质激素浓度是可取的。
• Substituted benzothiazole amide derivatives
  申请人：——

  公开号：US20030149036A1

  公开（公告）日：2003-08-07

  A compound of formula I and a method of treatment of diseases, related to modulation of the adenosine A 2 receptor system comprising administering a compound of formula 1 to a person in need of such treatment.

  公式I的化合物和一种治疗疾病的方法，与调节腺苷A2受体系统有关，包括给需要此类治疗的人口服公式1的化合物。
• 2,4,6-Tris-(substituted-amino)-s-triazines
  申请人：American Cyanamid Company

  公开号：US04261892A1

  公开（公告）日：1981-04-14

  This disclosure describes new compounds and compositions of matter useful as anti-inflammatory agents and as inhibitors of the progressive joint deterioration characteristic of arthritic disease and the methods of meliorating inflammation and of inhibiting joint deterioration in mammals therewith, the active ingredients of said compositions of matter being certain 2,4,6-tris(substituted-amino)-s-triazines.

  本公开说明了新的化合物和物质组成，可用作抗炎剂和阻止关节炎疾病特征性的进行性关节恶化的抑制剂，并描述了使用该化合物和物质组成来改善哺乳动物的炎症和抑制关节恶化的方法，该物质组成的活性成分是某些2,4,6-三（取代氨基）-s-三嗪。
• 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
  申请人：Ebdrup Soren

  公开号：US20100009968A1

  公开（公告）日：2010-01-14

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSDI and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文描述了使用取代酰胺来调节11β-羟基类固醇脱氢酶1型（11βHSD1）活性的方法，以及这些化合物作为药物组成物的用途。还介绍了一类新型的取代酰胺，其一般式为I。描述了它们在治疗中的应用、包含这些化合物的药物组成物，以及它们在制造药物方面的用途。这些化合物是11βHSDI活性的调节剂，更具体地说是抑制剂，可能在治疗需要降低细胞内活性糖皮质激素浓度的一系列医学疾病中有用。